|1.||Misra, Uma Kant: 1 article (04/2015)|
|2.||Pizzo, Salvatore Vincent: 1 article (04/2015)|
|3.||Chen, Yi-Ting: 1 article (04/2014)|
|4.||Huang, Wen-Chin: 1 article (04/2014)|
|5.||Li, Xiangyan: 1 article (04/2014)|
|6.||Hu, Peizhen: 1 article (04/2014)|
|7.||Shinohara, Tokuyuki: 1 article (08/2009)|
|8.||Kwon, Youngjoo: 1 article (08/2009)|
|9.||Asakura, Koko: 1 article (08/2009)|
|10.||Sakai, Juro: 1 article (08/2009)|
04/01/2014 - "In the present study, we evaluated the anti-prostate tumor activity of a novel SREBP inhibitor, fatostatin. "
04/01/2014 - "The in vivo animal results demonstrated that fatostatin significantly inhibited subcutaneous C4-2B tumor growth and markedly decreased serum prostate-specific antigen (PSA) level compared with the control group. "
|2.||Prostatic Neoplasms (Prostate Cancer)
04/01/2014 - "We found that fatostatin suppressed cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. "
04/10/2015 - "Lipogenesis is significantly affected by pretreatment of prostate cancer cells with fatostatin A, which blocks sterol regulatory element-binding protein proteolytic cleavage and activation. "
04/01/2014 - "Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling."
|3.||Body Weight (Weight, Body)
|1.||Prostate-Specific Antigen (Semenogelase)
|2.||Androgen Receptors (Androgen Receptor)
|3.||Carrier Proteins (Binding Protein)
|4.||Blood Glucose (Blood Sugar)